Summary and Recommendation
We reiterate our positive outlook on Bacterin International Holding, Inc. (NYSE MKT: BONE) shares given the company's recent hiring of new CEO Dan Goldberger and the satisfactory resolution of recent overhangs associated with the FDA and OIG inquiries.
Bacterin develops bone graft materials and biologic allografts for transplantation. The Company also develops bioactive coating technologies for implantable devices
Over the past 12 months shares of Bacterin International Holdings (NYSE MKT: BONE) have been under intense pressure having fallen from its highs of $1.82 to now below $0.60. The company has been wrought with a series of negative headlines from missing guidance, warning letters from the FDA, subpoena from the OIG and the departure of their Founder,...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|